Your search history is turned on.
Date: March 3, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003 The Company is receiving up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of its novel oral therapeutic for systemic hyperinflammation. ...
Date: March 1, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
Tetra Bio-Pharma Inc. Announces a Delay in Filing 2022 Annual Financial Statements and Related Management's Discussion and Analysis MONTREAL, QUEBEC TheNewswire March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discov...
Date: February 10, 2023 Jurisdictions: All jurisdictions
Tetra Bio-Pharma Announces Listing to OTCPink Market Tetra Bio-Pharma Announces Listing to OTCPink Market MONTREAL, Feb. 10, 2023 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC- PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, today announced that its common shares began trading on the OTC Markets Group's OTCPink Market in the United ...
Date: December 22, 2022 Jurisdictions: All jurisdictions
REDUVO Marketing Approval on the Right Path REDUVO Marketing Approval on the Right Path Second Clarifax received from Health Canada. MONTREAL, Dec. 22, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with another regulatory update on the REDUVO New ...
Date: December 6, 2022 Jurisdictions: All jurisdictions
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir The combination of ARDS-003 and Favipiravir presents viable treatments against viral infections. Results from the PIONEER clinical trial shows Favipiravir may improve severe COVID-19 recov...
Date: November 29, 2022 Jurisdictions: All jurisdictions
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS- 003. MONTREAL, Nov. 29, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (...
Date: November 18, 2022 Jurisdictions: All jurisdictions
Tetra Bio-Pharma Provides Update on Its REDUVO New Drug Submission Tetra Bio-Pharma Provides Update on Its REDUVO New Drug Submission MONTREAL, Nov. 18, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO New Drug ...
Date: October 27, 2022 Jurisdictions: All jurisdictions
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean OTTAWA, ON, Oct. 27, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that the Company has closed the second ...
Date: October 17, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Ontario, Price Edward Island, Quebec, Saskatchewan
_ 1 Tetra Bio-Pharma Inc. Form 52-109F2 Certification of Interim Filings Full Certificate I, Leslie Auld, Chief Financial Officer of Tetra Bio-Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Tetra- Bio-Pharma Inc. (the i...
_ 1 Tetra Bio-Pharma Inc. Form 52-109F2 Certification of Interim Filings Full Certificate I, Guy Chamberland, Chief Executive Officer of Tetra Bio-Pharma Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Tetra- Bio-Pharma Inc. (th...